This article describes several advances made in the dyslipidemia and cardiovascular prevention fields. These novelties pertain to the three steps of prevention: prediction including screening for two common, but often ignored, genetic abnormalities, namely familial hypercholesterolemia and elevated lipoprotein(a) levels, planning with the emergence in recommendations of a new target called "non-HDL cholesterol or non-HDL-C" in addition to the conventional "LDL-cholesterol or LDL-C" target, and prescription with the possible option of combining statins with other therapeutic classes.
Keywords
Cardiovascular diseases, cardiovascular prevention, lipoproteins, LDL-cholesterol, lipoprotein(a), familial hypercholesterolemia, genetics, atherosclerosis